Earth Science Tech, Inc. (ETST) Eyes Uplisting to
Post# of 333
(Total Views: 232)
Posted On: 02/07/2018 8:07:43 PM
Earth Science Tech, Inc. (ETST) Eyes Uplisting to OTCQB, Retains Counsel for Planned Regulation A+ Tier 2 Financing
- Goal is to raise $4 million to help company finance its planned projects
- Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
- ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases
Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://nnw.fm/If7xI). The funds would be used to finance its planned projects in the new year and for general working capital (http://nnw.fm/AvqM6), with share cancellation by company founders counteracting dilution.
ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://nnw.fm/cYPK2). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.
Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”
The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.
ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.
ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Goal is to raise $4 million to help company finance its planned projects
- Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
- ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases
Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://nnw.fm/If7xI). The funds would be used to finance its planned projects in the new year and for general working capital (http://nnw.fm/AvqM6), with share cancellation by company founders counteracting dilution.
ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://nnw.fm/cYPK2). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.
Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”
The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.
ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.
ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Earth Science Tech, Inc. (ETST) Stock Research Links
Scroll down for more posts ▼